Anticancer

Valepotriate
Catalog No: CFN90205

Valepotriates, a new class of cytotoxic and antitumor agents, they are very potent cytotoxic agents for the HTC hepatoma cells. Valepotriates may have a potential anxiolytic effect on the psychic symptoms of anxiety. Valepotriate fraction can have sedative effects and affect behavioral parameters related to recognition memory.

Curzerene
Catalog No: CFN90206

Curzerene may be used as an anti-lung adenocarcinoma drug candidate compound for further development, it can induce the downregulation of GSTA1 protein and mRNA expressions in SPC-A1 cells, it can cure and prevent breast precancer.

Glaucocalyxin A
Catalog No: CFN90207

Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand. Glaucocalyxin A has regulation of microglia activity, can attenuate lipopolysaccharide -stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways.Glaucocalyxin A may become a potential anti-fibrotic agent in Idiopathic pulmonary fibrosis (IPF) management, it can effectively ameliorate pulmonary fibrosis through the antagonism of leukocyte infiltration and proinflammatory cytokine production.

Cucurbitacin D
Catalog No: CFN90209

Cucurbitacin D has anticancer effects, it induces apoptosis through caspase-3 and phosphorylation of JNK in hepatocellular carcinoma cells. Cucurbitacin D may be a potential therapeutic agent for β-hemoglobinopathies, including sickle cell anemia and β-thalassemia. Cucurbitacin D is a new inflammasome activator in macrophages, it can initiate immunomodulating activity in macrophages to lead to inflammasome activation as well as enhancement of LPS signaling.

Diosmetin
Catalog No: CFN90210

Diosmetin has anti-osteoporosis, cytoprotective, antibacterial, anti-pigmentation, anti-inflammatory and antioxidant properties, it induces osteoblastic differentiation through the PKCδ-Rac1-MEK3/6-p38 and PKCδ-Rac1-MEK1/2- ERK1/2-Runx2 pathways.Diosmetin has intracellular antioxidant detoxifying effect, the mechanism is associated with both nonenzymatic and enzymatic defense systems.Diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation.